RUJA: Repositorio Institucional de Producción Científica

 

Lipid nanoparticles for the transport of drugs like dopamine through the blood–brain barrier

dc.contributor.authorOrtega-Escandell, Elena
dc.contributor.authorBlanco-Ruiz, Santos
dc.contributor.authorRuiz-Martínez, María Adolfina
dc.contributor.authorPeinado-Herreros, María Ángeles
dc.contributor.authorPeralta, Sebastián
dc.contributor.authorMorales-Hernández, María Encarnación
dc.date.accessioned2024-02-08T08:10:08Z
dc.date.available2024-02-08T08:10:08Z
dc.date.issued2021
dc.description.abstractDiseases and disorders of the nervous system, like Parkinson disease (PD) and other neurodegenerative pathologies, are widespread in our society. The arsenal of treatments against these pathologies continues to increase, but in many cases, its use is limited. This is due to the blood-brain barrier (BBB), which acts by limiting the penetration of drugs into the brain. To overcome this handicap, in the current research, solid lipid nanoparticles (SLNPs) able to encapsulate drugs and to cross the blood-brain barrier have been designed to transport and release these drugs into their targets. These SLNPs were synthesized by a sonication method and high agitation process searching the most adequate physicochemical profile to achieve the objectives set. Today, the most efficient treatment for PD consists of providing the dopamine (DP) that is lost by neurodegeneration; however, the nature of this neurotransmitter prevents its crossing of the BBB. Therefore, DP may be considered as a good candidate to be encapsulated in SLNPs while studying how the loading drug could affect such nanoparticles. Based on these antecedents, in this research, both empty and DP-charged SLNPs were characterized physicochemically. The results obtained indicated a great stability of the nanoparticles loaded with DP when drug was used at 0.2 to 0.05%; these concentrations barely affected its size, polydispersity, and ζ-potential, and the SLNPs elaborated in this research were high appropriate to be injected systemically. Finally, empty SLNPs labeled and administered systemically to adult male Wistar rats demonstrate their penetration ability into the brain parenchyma.
dc.identifier.issn1388-0764es_ES
dc.identifier.otherhttps://doi.org/10.1007/s11051-021-05218-0es_ES
dc.identifier.urihttps://hdl.handle.net/10953/2229
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.ispartofJ. Nanopart. Res. [2021];[23]:[106]es_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectDopaminees_ES
dc.subjectNanoparticleses_ES
dc.subjectBrain–blood barrieres_ES
dc.subjectNeurodegenerative diseaseses_ES
dc.titleLipid nanoparticles for the transport of drugs like dopamine through the blood–brain barrieres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.versioninfo:eu-repo/semantics/acceptedVersiones_ES

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
AIN024 · Ortega et al. Q3 JCR · 2021.pdf
Tamaño:
840.2 KB
Formato:
Adobe Portable Document Format
Descripción:
# The Author(s), under exclusive licence to Springer Nature B.V. 2021

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones